¹⁵³Sm -DOTA-phosphine-ruthenium and gold bimetallic complexes as new radio-theranostics

Full text of publication follows. Since the pioneer discovery of cisplatin for biological applications by Rosenberg in the 1960's [Ref.1] metal complexes have become the most currently investigated and used class of compounds in cancer chemotherapy [Ref.2]. However in most cases, their mechanisms of action are still poorly understood. Imaging drugs aimed at understanding their mechanism of action and studying their pharmacokinetics is thus one of the key challenges of medicinal chemists today. To take up this challenge new DOTA-phosphine compounds were synthesized. It is a versatile tool to image organometallic complexes, and allowed the access to an unprecedented family of theranostics featuring Au and Ru complexes for the therapeutic moiety and ¹⁵³Sm for the imaging part. The radiolabelling of the ligand was studied and the stability of corresponding complexes was evaluated. Their cytotoxicity was also tested on cancer cells, and their biodistribution was determined in vivo. References: [1] Rosenberg, B.; VanCamp, L.; Krigas, T., Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode, Nature 1965, 205, 698-699; [2] Zhang, C. X.; Lippard, S. J., New metal complexes as potential therapeutics, Curr. Opin. Chem. Biol. 2003, 7, 481-489. (authors)